📊 This integration allows real-time sampling and analysis of cell culture parameters, improving efficiency in process development. It aims to optimize workflows for cell-based therapies and enhance monitoring during production. 🧬
Introduction:
The collaboration between Terumo Blood and Cell Technologies (Terumo BCT) and Nova Biomedical aims to enhance automated cell culture sensing through the integration of Terumo BCT’s Quantum Flex™ cell expansion system with Nova’s BioProfile FLEX2 automated cell culture analyzer. This partnership seeks to improve the efficiency and reliability of cell-based therapies, particularly during the critical cell culture stage of development.
- Terumo BCT and Nova Biomedical are collaborating to enable automated cell culture sensing, enhancing the capabilities of the Quantum Flex™ system.
- The integration with the BioProfile FLEX2 allows for online automated sampling and analysis of multiple analytes, providing near-real-time data.
- The capabilities of automated cell culture monitoring are essential for optimizing therapeutic processes and improving workflow efficiency.
- The FLEX2 will facilitate better insight and control from process development to commercial manufacturing, addressing customer demands in the cell therapy sector.
- Utilizing FLEX2 technology is expected to enhance process monitoring, reduce reagent use, and improve overall outputs in cell culture.
Conclusion:
The collaboration between Terumo BCT and Nova Biomedical marks a significant advancement in automated cell culture sensing technology. This integration is anticipated to streamline the development and production of cell therapies, enhancing process control and efficiency. As the demand for reliable cell-based therapies grows, such innovations are critical for improving therapeutic outcomes and expediting market readiness.
